Clarivate/$CLVT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Clarivate
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.
- Ticker
- $CLVT
- Sector
- Business services
- Primary listing
- NYSE
- Employees
- 12,000
- Headquarters
- London, United Kingdom
- Website
- www.clarivate.com
Clarivate Metrics
BasicAdvanced
$1.5B
-
-$0.60
1.39
-
Price and volume
Market cap
$1.5B
Beta
1.39
52-week high
$3.87
52-week low
$1.42
Average daily volume
4.1M
Financial strength
Current ratio
0.877
Quick ratio
0.715
Long term debt to equity
0.923
Total debt to equity
0.927
Interest coverage (TTM)
0.74%
Profitability
EBITDA (TTM)
903.1
Gross margin (TTM)
67.88%
Net profit margin (TTM)
-16.23%
Operating margin (TTM)
7.64%
Effective tax rate (TTM)
-1.47%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
1.26%
Return on equity (TTM)
-2.34%
Valuation
Price to revenue (TTM)
0.632
Price to book
0.33
Price to tangible book (TTM)
-0.4
Price to free cash flow (TTM)
4.672
Free cash flow yield (TTM)
21.41%
Free cash flow per share (TTM)
0.501
Growth
Revenue change (TTM)
7.75%
Earnings per share change (TTM)
4.72%
3-year revenue growth (CAGR)
-3.14%
3-year earnings per share growth (CAGR)
32.30%
What the Analysts think about Clarivate
Analyst ratings (Buy, Hold, Sell) for Clarivate stock.
Analyst projections of the future price of Clarivate stock.
Bulls say / Bears say
Recurring organic revenue growth reached 1.3% in the third quarter, while organic annual contract value grew 1.8% and IP returned to positive ACV growth. That points to a gradual recovery in the contracted revenue base. (Clarivate)
The Life Sciences & Healthcare sale has made Clarivate more focused on its Academia & Government and Intellectual Property businesses, and brought in $488.4 million in net cash proceeds. Management says it plans to use the proceeds to reduce debt, which could ease interest costs and improve financial flexibility. (Clarivate)
Clarivate says its new AI-native Web of Science Research Intelligence platform has been adopted by more than 100 institutions in 25 countries. Management also reported a roughly $20 million sales pipeline for 2026–27, offering a potential route to new recurring revenue if interest converts into sales. (Clarivate, Investing.com)
Revenue from continuing operations fell 9.2% year on year to $481.6 million in the third quarter and missed analysts’ expectations, despite a small rise in organic revenue. The updated 2026 revenue outlook leaves little room for a strong near-term rebound. (Yahoo Finance, Clarivate)
The shift to recurring products has not yet offset weakness in transactional business: third-quarter organic transactional revenue fell 12.4%, and recurring growth was only 1.3%. Continued product wind-downs and softer customer activity could keep overall growth subdued. (Clarivate)
Debt remained high at $4.18 billion at the end of September, while free cash flow for the first nine months fell to $233.1 million from $276.1 million a year earlier. That limits the room to invest or absorb further operating setbacks even after the asset sale. (Clarivate)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
Clarivate Financial Performance
Revenues and expenses
Clarivate Earnings Performance
Company profitability
Upcoming events
No upcoming events
Clarivate News
AllArticlesVideos
Funds containing Clarivate
AllUSDEURGBP
Fund name | Fund size | $CLVT weighting |
|---|---|---|
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.04% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.